
Opinion|Videos|April 14, 2025
Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
Panelists discuss how response rates, progression-free survival, and overall survival data presented at the European Lung Cancer Conference (ELCC 2025) demonstrate meaningful clinical outcomes while highlighting important safety considerations for patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5








































